vs
Side-by-side financial comparison of KEMPER Corp (KMPR) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
KEMPER Corp is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.6× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -0.7%, a 19.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -4.7%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $166.2M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -0.5%).
Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
KMPR vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $708.5M |
| Net Profit | $-8.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | — | 21.6% |
| Net Margin | -0.7% | 19.1% |
| Revenue YoY | -4.7% | 32.0% |
| Net Profit YoY | -108.2% | 15.5% |
| EPS (diluted) | $-0.03 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $708.5M | ||
| Q3 25 | $1.2B | $659.9M | ||
| Q2 25 | $1.2B | $603.3M | ||
| Q1 25 | $1.2B | $558.6M | ||
| Q4 24 | $1.2B | $536.6M | ||
| Q3 24 | $1.2B | $533.3M | ||
| Q2 24 | $1.1B | $528.1M | ||
| Q1 24 | $1.1B | $511.0M |
| Q4 25 | $-8.0M | $135.1M | ||
| Q3 25 | $-21.0M | $111.1M | ||
| Q2 25 | $72.6M | $90.3M | ||
| Q1 25 | $99.7M | $114.6M | ||
| Q4 24 | $97.4M | $117.0M | ||
| Q3 24 | $73.7M | $96.4M | ||
| Q2 24 | $75.4M | $88.4M | ||
| Q1 24 | $71.3M | $102.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | 11.2% | 21.1% | ||
| Q2 24 | 10.1% | 19.9% | ||
| Q1 24 | 7.6% | 20.4% |
| Q4 25 | -0.7% | 19.1% | ||
| Q3 25 | -1.7% | 16.8% | ||
| Q2 25 | 5.9% | 15.0% | ||
| Q1 25 | 8.4% | 20.5% | ||
| Q4 24 | 8.2% | 21.8% | ||
| Q3 24 | 6.3% | 18.1% | ||
| Q2 24 | 6.7% | 16.7% | ||
| Q1 24 | 6.2% | 20.1% |
| Q4 25 | $-0.03 | $4.65 | ||
| Q3 25 | $-0.34 | $3.86 | ||
| Q2 25 | $1.12 | $3.10 | ||
| Q1 25 | $1.54 | $3.67 | ||
| Q4 24 | $1.51 | $3.67 | ||
| Q3 24 | $1.14 | $3.01 | ||
| Q2 24 | $1.16 | $2.75 | ||
| Q1 24 | $1.10 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | $943.5M | — |
| Stockholders' EquityBook value | $2.7B | $459.1M |
| Total Assets | $12.5B | $2.0B |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $497.0M | ||
| Q3 25 | $371.2M | $285.4M | ||
| Q2 25 | $407.6M | $46.3M | ||
| Q1 25 | $545.3M | $441.4M | ||
| Q4 24 | $1.0B | $669.4M | ||
| Q3 24 | $696.9M | $656.9M | ||
| Q2 24 | $539.1M | $510.9M | ||
| Q1 24 | $520.7M | $407.0M |
| Q4 25 | $943.5M | — | ||
| Q3 25 | $943.1M | — | ||
| Q2 25 | $942.6M | — | ||
| Q1 25 | $942.1M | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $2.7B | $459.1M | ||
| Q3 25 | $2.7B | $293.6M | ||
| Q2 25 | $370.0M | $172.4M | ||
| Q1 25 | $366.0M | $593.6M | ||
| Q4 24 | $2.8B | $825.5M | ||
| Q3 24 | $2.8B | $881.4M | ||
| Q2 24 | $358.0M | $763.6M | ||
| Q1 24 | $2.6B | $671.5M |
| Q4 25 | $12.5B | $2.0B | ||
| Q3 25 | $12.4B | $1.8B | ||
| Q2 25 | $12.6B | $1.6B | ||
| Q1 25 | $12.5B | $1.9B | ||
| Q4 24 | $12.6B | $2.1B | ||
| Q3 24 | $12.6B | $2.1B | ||
| Q2 24 | $12.6B | $1.9B | ||
| Q1 24 | $12.6B | $1.8B |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.57× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 3.88× | — | ||
| Q1 24 | 0.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.0M | $192.7M |
| Free Cash FlowOCF − Capex | $166.2M | $188.1M |
| FCF MarginFCF / Revenue | 14.7% | 26.6% |
| Capex IntensityCapex / Revenue | 0.8% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $553.9M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.0M | $192.7M | ||
| Q3 25 | $139.9M | $246.2M | ||
| Q2 25 | $89.6M | $148.5M | ||
| Q1 25 | $180.0M | $125.8M | ||
| Q4 24 | $175.1M | $190.7M | ||
| Q3 24 | $141.9M | $149.1M | ||
| Q2 24 | $22.9M | $116.4M | ||
| Q1 24 | $43.0M | $152.7M |
| Q4 25 | $166.2M | $188.1M | ||
| Q3 25 | $133.4M | $235.5M | ||
| Q2 25 | $82.0M | $142.4M | ||
| Q1 25 | $172.3M | $115.8M | ||
| Q4 24 | $165.4M | $183.0M | ||
| Q3 24 | $131.4M | $138.5M | ||
| Q2 24 | $5.2M | $103.5M | ||
| Q1 24 | $27.7M | $147.2M |
| Q4 25 | 14.7% | 26.6% | ||
| Q3 25 | 10.8% | 35.7% | ||
| Q2 25 | 6.7% | 23.6% | ||
| Q1 25 | 14.4% | 20.7% | ||
| Q4 24 | 13.9% | 34.1% | ||
| Q3 24 | 11.1% | 26.0% | ||
| Q2 24 | 0.5% | 19.6% | ||
| Q1 24 | 2.4% | 28.8% |
| Q4 25 | 0.8% | 0.6% | ||
| Q3 25 | 0.5% | 1.6% | ||
| Q2 25 | 0.6% | 1.0% | ||
| Q1 25 | 0.6% | 1.8% | ||
| Q4 24 | 0.8% | 1.4% | ||
| Q3 24 | 0.9% | 2.0% | ||
| Q2 24 | 1.6% | 2.4% | ||
| Q1 24 | 1.3% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 1.23× | 1.65× | ||
| Q1 25 | 1.81× | 1.10× | ||
| Q4 24 | 1.80× | 1.63× | ||
| Q3 24 | 1.93× | 1.55× | ||
| Q2 24 | 0.30× | 1.32× | ||
| Q1 24 | 0.60× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
